

What is claimed is:

1. A composition comprising a caspase inhibitor and a non-caspase inhibitor anti-cancer agent.
2. The composition of claim 1, wherein the caspase inhibitor is a pan caspase inhibitor.
3. The composition of claim 2, wherein the caspase inhibitor is selected from the group consisting of inhibitors of caspase 9, caspase-3, caspase-8 or pan-caspase inhibitors.
4. The composition of claim 1, wherein the caspase inhibitor inhibits the production of a caspase.
5. The composition of claim 1, wherein the caspase inhibitor inhibits the activation of a caspase.
6. The composition of claim 1, wherein the caspase inhibitor inhibits a signaling pathway of a caspase.
7. The composition of claim 1-7, wherein the non-caspase anti-cancer agent is selected from the group consisting of alkylating agents, DNA strand breaking agents, antimetabolites, topoisomerase inhibitors, tubulin interactive agents, and mitotic inhibitors.
8. The composition of claim 1-7, wherein the non-caspase inhibitor anti-cancer agent is BCNU.
9. The composition of claims 1-7, further comprising an antioxidant.
10. The composition of claims 1-7, wherein the anti-cancer agent is itself an anti-oxidant.
11. The composition of claims 10-11, wherein the antioxidant is vitamin C or a glutathione pro-drug.

12. The composition of claim 1-12, further comprising a pharmaceutical carrier.
13. A method of inhibiting the growth of a cancer cell comprising introducing the composition of claims 1-13 to the cell.
14. The method of claim 14, wherein the cancer cell is killed.
15. A method of treating a subject having cancer comprising administering the composition of claim 13 to the subject.
16. A method of inhibiting the growth of a cancer cell comprising introducing a caspase inhibitor to the cell.
17. The method of claim 17, wherein the cancer cell is killed.
18. A method of treating a subject having cancer comprising administering a caspase inhibitor in a pharmaceutically acceptable form to the subject .
19. The method of claims 17-19, wherein the caspase inhibitor is a pan caspase inhibitor.
20. The method of claims 17-19, wherein the caspase inhibitor is specific for caspase-3, caspase-8 or caspase-9.
21. The method of claims 17-19, wherein the caspase inhibitor inhibits the production of a caspase.
22. The method of claims 17-19, wherein the caspase inhibitor inhibits the activation of a caspase.
23. The method of claims 17-19, wherein the caspase inhibitor inhibits a signaling pathway of a caspase.
24. A composition comprising a caspase inhibitor and an antioxidant.
25. The composition of claim 26, wherein the caspase inhibitor is a pan caspase inhibitor.

26. The composition of claim 26, wherein the caspase inhibitor is specific for a caspase selected from the group consisting of caspase-3, caspase-8 or caspase-9.
27. The composition of claim 26, wherein the caspase inhibitor inhibits the production of a caspase.
28. The composition of claim 26, wherein the caspase inhibitor inhibits the activation of a caspase.
29. The composition of claim 26, wherein the caspase inhibitor inhibits a signaling pathway of a caspase.
30. The composition of claim 26-32, wherein antioxidant is selected from the group consisting of non-flavonoid antioxidants, multi-carotenes, beta-carotenes, alpha-carotenes, gamma-carotenes, lycopene, lutein and zeaxanthins, selenium, Vitamin E, tocopherol, vitamin E succinate, trolox, Vitamin C, Niacin, Vitamin A, 13-cis retinoic acid, N-acetyl-L-cysteine, glutathione pro-drugs, sodium ascorbate, pyrrolidinedithiocarbamate, coenzyme Q10; peroxidases; glutathione peroxidase, catalase, superoxide dismutase; glutathione transferase, glutathione reductase, glucose 6-phosphate dehydrogenase, glutathione; ceruloplasmin, cysteine, cysteamine, flavenoids, and mimetics, analogs and polymers thereof.
31. The composition of claim 26-32, wherein the antioxidant is vitamin C.
32. The composition of claims 1-7, further comprising a non-caspase anticancer agent.
33. The composition of claim 26-32, wherein the antioxidant is vitamin C.
34. The composition of claim 26-36, further comprising a pharmaceutical carrier.
35. A method of inhibiting the growth of a cancer cell comprising introducing the composition of claims 26-37 to the cell.
36. The method of claim 38, wherein the cancer cell is killed.

37. A method of treating a subject having cancer comprising administering the composition of claim 38 to the subject.